Option Care Health (NASDAQ:OPCH) Cut to “Hold” at Zacks Investment Research

Option Care Health (NASDAQ:OPCHGet Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Tuesday, Zacks.com reports.

According to Zacks, “Option Care Health Inc provides infusion and home care management solutions. The Company offers products, services and condition-specific clinical management programs for gastrointestinal abnormalities, infectious diseases, cancer, organ and blood cell transplants, bleeding disorders and heart failures. Option Care Health Inc., formerly known as BioScrip Inc., is based in Denver, United States. “

A number of other analysts have also weighed in on the stock. Deutsche Bank Aktiengesellschaft raised their price target on shares of Option Care Health from $32.00 to $39.00 in a report on Friday. Barrington Research raised their price target on shares of Option Care Health from $31.00 to $33.00 in a report on Friday. Finally, TheStreet lowered shares of Option Care Health from a “b” rating to a “c+” rating in a report on Thursday, April 28th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $31.17.

NASDAQ:OPCH opened at $28.44 on Tuesday. Option Care Health has a 1 year low of $16.02 and a 1 year high of $30.70. The firm has a 50 day moving average price of $27.42. The company has a quick ratio of 1.15, a current ratio of 1.55 and a debt-to-equity ratio of 0.90. The company has a market capitalization of $5.13 billion, a PE ratio of 29.63, a P/E/G ratio of 1.46 and a beta of 1.38.

Option Care Health (NASDAQ:OPCHGet Rating) last posted its earnings results on Thursday, April 28th. The company reported $0.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.13 by $0.04. Option Care Health had a net margin of 4.81% and a return on equity of 12.85%. The company had revenue of $915.78 million during the quarter, compared to analysts’ expectations of $839.45 million. During the same quarter in the previous year, the company posted ($0.02) earnings per share. Option Care Health’s quarterly revenue was up 20.6% compared to the same quarter last year. On average, analysts anticipate that Option Care Health will post 0.94 earnings per share for the current fiscal year.

In other Option Care Health news, COO Harriet Booker sold 6,000 shares of Option Care Health stock in a transaction on Wednesday, April 6th. The shares were sold at an average price of $27.18, for a total transaction of $163,080.00. Following the completion of the sale, the chief operating officer now owns 81,511 shares of the company’s stock, valued at approximately $2,215,468.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold a total of 18,000 shares of company stock valued at $461,460 in the last ninety days. Company insiders own 0.22% of the company’s stock.

Hedge funds have recently made changes to their positions in the company. Compagnie Lombard Odier SCmA acquired a new position in shares of Option Care Health in the 4th quarter valued at $31,000. Covestor Ltd acquired a new position in shares of Option Care Health in the 4th quarter valued at $46,000. US Bancorp DE grew its holdings in shares of Option Care Health by 16.4% in the 3rd quarter. US Bancorp DE now owns 2,843 shares of the company’s stock valued at $69,000 after buying an additional 400 shares during the period. Sheaff Brock Investment Advisors LLC acquired a new position in shares of Option Care Health in the 4th quarter valued at $201,000. Finally, Lincoln National Corp bought a new stake in Option Care Health in the 4th quarter valued at $206,000. 98.23% of the stock is owned by institutional investors.

Option Care Health Company Profile (Get Rating)

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including Crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.

Featured Articles

Get a free copy of the Zacks research report on Option Care Health (OPCH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Option Care Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Option Care Health and related companies with MarketBeat.com's FREE daily email newsletter.